Literature DB >> 10072548

TGF-beta does not inhibit IL-12- and IL-2-induced activation of Janus kinases and STATs.

C Sudarshan1, J Galon, Y Zhou, J J O'Shea.   

Abstract

The immune system is an important target for the cytokine TGF-beta1, whose actions on lymphocytes are largely inhibitory. TGF-beta has been reported to inhibit IL-12- and IL-2-induced cell proliferation and IFN-gamma production by T cells and NK cells; however, the mechanisms of inhibition have not been clearly defined. It has been suggested by some studies that TGF-beta blocks cytokine-induced Janus kinase (JAK) and STAT activation, as in the case of IL-2. In contrast, other studies with cytokines like IFN-gamma have not found such an inhibition. The effect of TGF-beta on the IL-12-signaling pathway has not been addressed. We examined this and found that TGF-beta1 did not have any effect on IL-12-induced phosphorylation of JAK2, TYK2, and STAT4 although TGF-beta1 inhibited IL-2- and IL-12-induced IFN-gamma production. Similarly, but in contrast to previous reports, we found that TGF-beta1 did not inhibit IL-2-induced phosphorylation of JAK1, JAK3, and STAT5A. Furthermore, gel shift analysis showed that TGF-beta1 did not prevent activated STAT4 and STAT5A from binding to DNA. Our results demonstrate that the inhibitory effects of TGF-beta on IL-2- and IL-12-induced biological activities are not attributable to inhibition of activation of JAKs and STATs. Rather, our data suggest the existence of alternative mechanisms of inhibition by TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072548

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.

Authors:  Cheryn Song; Sun-Young Jun; Jun-Hyuk Hong; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-06       Impact factor: 4.553

2.  TGF-β inhibits IL-7-induced proliferation in memory but not naive human CD4+ T cells.

Authors:  Thao P Nguyen; Scott F Sieg
Journal:  J Leukoc Biol       Date:  2017-06-06       Impact factor: 4.962

3.  TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.

Authors:  Rossana Trotta; Jessica Dal Col; Jianhua Yu; David Ciarlariello; Brittany Thomas; Xiaoli Zhang; Jeffrey Allard; Min Wei; Hsiaoyin Mao; John C Byrd; Danilo Perrotti; Michael A Caligiuri
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 4.  Cellular and molecular mechanisms of memory T-cell survival.

Authors:  Andre Tanel; Simone G Fonseca; Bader Yassine-Diab; Rebeka Bordi; Joumana Zeidan; Yu Shi; Clarisse Benne; Rafick-Pierre Sékaly
Journal:  Expert Rev Vaccines       Date:  2009-03       Impact factor: 5.217

Review 5.  A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12.

Authors:  David J Klinke
Journal:  Mol Cancer       Date:  2010-09-15       Impact factor: 27.401

6.  Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.

Authors:  Geok Choo Sim; Sheng Wu; Lei Jin; Patrick Hwu; Laszlo G Radvanyi
Journal:  Oncotarget       Date:  2016-06-14

7.  Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.

Authors:  Yan Lan; Tsz-Lun Yeung; Hui Huang; Ansgar A Wegener; Somdutta Saha; Mira Toister-Achituv; Molly H Jenkins; Li-Ya Chiu; Adam Lazorchak; Ohad Tarcic; Hong Wang; Jin Qi; George Locke; Doron Kalimi; Guozhong Qin; Bo Marelli; Huakui Yu; Alec W Gross; Melissa G Derner; Maria Soloviev; Mathieu Botte; Aroop Sircar; Hong Ma; Vanita D Sood; Dong Zhang; Feng Jiang; Kin-Ming Lo
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.